Results from a randomized phase 3 trial of Sutent (sunitinib malate) indicate that patients with pancreatic neuroendocrine tumours are able to live longer
Results from a randomized phase 3 trial of Sutent (sunitinib malate) indicate that patients with pancreatic neuroendocrine tumours are able to live longer if they take the medication as compared with patients treated with placebo, Pfizer Inc has announced.
"This trial advances our understanding of the use of novel targeted therapies in a patient population with limited treatment options," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer’s Oncology Business Unit. "We are pleased to be working toward filling an unmet patient need, as we did with Sutent four years ago in patients with kidney cancer and gastrointestinal stromal tumours."
Pancreatic Cancer - All About the Disease, its Diagnosis and Management
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.
The details of the phase 3 study were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
Research Offers Alternative Method of Pancreatic Biopsy
Endoscopic ultrasound-guided biopsy of pancreatic masses has been proved to be a safe and effective method as an alternative method of pancreatic biopsy, by new research.
Endoscopic ultrasound-guided biopsy of pancreatic masses has been proved to be a safe and effective method as an alternative method of pancreatic biopsy, by new research.
RAS
Pancreatic Tumor Aggressiveness can be Predicted by Blood-Flow Metabolism Mismatch
A blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness has been identified by researchers from Turku, Finland.
A blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness has been identified by researchers from Turku, Finland.
Feasibility of Enhancing Pancreatic Cancer on Dynamic CT Debated
It has been clarified that the grade of tumor angiogenesis is a useful prognostic marker in human cancer, including pancreatic cancer in recent research.
It has been clarified that the grade of tumor angiogenesis is a useful prognostic marker in human cancer, including pancreatic cancer in recent research.
